The FDA will require diabetes drug manufacturers to meet more rigorous standards, in an effort to lower the risk for heart problems.
The policy change reacts to studies that found an increased risk for heart failure and heart attack linked to certain diabetes drugs.
Manufacturers will now have to test the drugs in older, high risk populations. The trials will have to last longer to allow time for subtle side effects to emerge. An independent committee will have to monitor heart attack and stroke rates.